XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)
 6 Months Ended
Jun. 30, 2022
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Revenue related to Novartis agreement:
Recognition of upfront license fee$8,622 $7,559 $15,640 $13,759 
Research services2,306 2,022 4,183 3,683 
Total$10,928 $9,581 $19,823 $17,442 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Revenue related to Biogen agreement:
Recognition of license and stand-ready fee$7,306 $7,306 $14,612 $14,612 
Research services2,746 3,461 6,633 6,605 
Total$10,052 $10,767 $21,245 $21,217 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Revenue related to Kite agreement:
Recognition of license and stand-ready fee$6,227 $6,227 $12,386 $12,386 
Research services107 97 256 226 
Total$6,334 $6,324 $12,642 $12,612 
Sanofi S.A.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Revenue related to Sanofi agreement:
Recognition of upfront fee$366 $206 $677 $433 
Research services1,148 613 2,126 1,292 
Milestone achievement247 138 457 292 
Total$1,761 $957 $3,260 $2,017